Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy.

Authors	Kentaro Ohuchi, Ryo Amagai, Erika Tamabuchi, Yumi Kambayashi, Taku Fujimura
Journal	The Journal of dermatology (J Dermatol) Vol. 49 Issue 5 Pg. e167-e168 (05 2022) ISSN: 1346-8138 [Electronic] England
PMID	35014070 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References	Ipilimumab Nivolumab
Topics	COVID-19 (prevention & control) Diabetes Mellitus, Type 1 Endocrine System Diseases Humans Ipilimumab Melanoma (drug therapy) Nivolumab (adverse effects) Vaccination

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!